Literature DB >> 17035348

Differential induction of Th1-prone immunity by human dendritic cells activated with Sporothrix schenckii of cutaneous and visceral origins to determine their different virulence.

Takeshi Uenotsuchi1, Satoshi Takeuchi, Tetsuo Matsuda, Kazunori Urabe, Tetsuya Koga, Hiroshi Uchi, Takeshi Nakahara, Shuji Fukagawa, Masako Kawasaki, Hideko Kajiwara, Shin-Ichi Yoshida, Yoichi Moroi, Masutaka Furue.   

Abstract

Sporotrichosis is caused by a thermo-dependent dimorphic fungus, Sporothrix schenckii. The major clinical manifestations occur in the skin; however, cases of visceral manifestations have also been increasingly reported with some being observed in immune compromised patients. Different virulence of individual S. schenckii strain as well as immune status of the host could contribute to form such different clinical manifestations. Thus, the purpose of the study was to investigate whether different virulence of individual S. schenckii could be a factor for such clinical difference. We investigated the interactions between human monocyte-derived dendritic cells (MoDCs) and S. schenckii, assessed by (i) morphological features, (ii) surface marker expressions, cytokine productions, (iii) signaling pathways and (iv) allostimulatory activity of the activated MoDCs. Immature MoDCs, obtained from peripheral blood monocytes supplemented with granulocyte macrophage colony-stimulating factor and IL-4, were stimulated with S. schenckii strains of both yeasts and conidia forms of different origins (cutaneous isolates: KMU4649, IFM5906 and IFM46010; visceral isolates: KMU4648, IFM41598 and ATCC26331) to be used for various assays. Through the analysis, we found that the cutaneous S. shenckii of cutaneous origins were more potent to activate MoDCs to induce strong T(h)1 response, as evidenced by abundant IFN-gamma production, while the S. shenckii of visceral origins induced only minimal dendritic cell activation and T(h)1 induction. The p38 mitogen-activated protein kinase and c-Jun N-terminal kinase signaling pathways appeared to be associated with the differential activation of the MoDCs by S. schenckii of cutaneous and the visceral origins. Overall, we concluded that the differential activation of MoDCs by S. schenckii of cutaneous and visceral origins to induce T(h)1 response, other than immune status or the host, may be a factor for their different clinical manifestations.

Entities:  

Mesh:

Year:  2006        PMID: 17035348     DOI: 10.1093/intimm/dxl097

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  20 in total

1.  Variation in genotype and higher virulence of a strain of Sporothrix schenckii causing disseminated cutaneous sporotrichosis.

Authors:  Zhenying Zhang; Xiaoming Liu; Xuelian Lv; Jingrong Lin
Journal:  Mycopathologia       Date:  2011-06-30       Impact factor: 2.574

2.  Prophylactic and therapeutic vaccination using dendritic cells primed with peptide 10 derived from the 43-kilodalton glycoprotein of Paracoccidioides brasiliensis.

Authors:  A Magalhães; K S Ferreira; S R Almeida; J D Nosanchuk; L R Travassos; C P Taborda
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

Review 3.  Sporothrix schenckii and Sporotrichosis.

Authors:  Mônica Bastos de Lima Barros; Rodrigo de Almeida Paes; Armando Oliveira Schubach
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

4.  Human sporotrichosis: recommendations from the Brazilian Society of Dermatology for the clinical, diagnostic and therapeutic management.

Authors:  Rosane Orofino-Costa; Dayvison Francis Saraiva Freitas; Andréa Reis Bernardes-Engemann; Anderson Messias Rodrigues; Carolina Talhari; Claudia Elise Ferraz; John Verrinder Veasey; Leonardo Quintella; Maria Silvia Laborne Alves de Sousa; Rodrigo Vettorato; Rodrigo de Almeida-Paes; Priscila Marques de Macedo
Journal:  An Bras Dermatol       Date:  2022-09-22       Impact factor: 2.113

Review 5.  Molecular Components of the Sporothrix schenckii Complex that Induce Immune Response.

Authors:  Carlos A Alba-Fierro; Armando Pérez-Torres; Conchita Toriello; Yolanda Romo-Lozano; Everardo López-Romero; Estela Ruiz-Baca
Journal:  Curr Microbiol       Date:  2016-04-27       Impact factor: 2.188

Review 6.  Current research on the immune response to experimental sporotrichosis.

Authors:  Iracilda Zeppone Carlos; Micheli Fernanda Sassá; Diana Bridon da Graça Sgarbi; Marisa Campos Polesi Placeres; Danielle Cardoso Geraldo Maia
Journal:  Mycopathologia       Date:  2009-02-25       Impact factor: 2.574

7.  Response of macrophage Toll-like receptor 4 to a Sporothrix schenckii lipid extract during experimental sporotrichosis.

Authors:  Micheli F Sassá; Ana E T Saturi; Lucas F Souza; Livia C de Abreu Ribeiro; Diana B da Graça Sgarbi; Iracilda Z Carlos
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

Review 8.  Biological and Clinical Attributes of Sporothrix globosa, a Causative Agent of Sporotrichosis.

Authors:  Laura C García-Carnero; Héctor M Mora-Montes; Nallely Nava-Pérez; Lisset G Neri-García; Oscar E Romero-González; Joshua A Terrones-Cruz
Journal:  Infect Drug Resist       Date:  2022-04-22       Impact factor: 4.177

9.  Therapeutic monoclonal antibody for sporotrichosis.

Authors:  Sandro R Almeida
Journal:  Front Microbiol       Date:  2012-11-28       Impact factor: 5.640

10.  Taenia taeniaeformis in rat favors protracted skin lesions caused by Sporothrix schenckii infection: Dectin-1 and IL-17 are dispensable for clearance of this fungus.

Authors:  Xiaohui Zhang; Jing Zhang; Huaiqiu Huang; Ruzeng Xue; Xuchu Hu; Meirong Li; Yi Zhong; Liyan Yuan
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.